The role of interdisciplinary cooperation in the prevention of Medication-Related Osteonecrosis of the Jaw (MRONJ)

Introduction

Bisphosphonate-Related Osteonecrosis of the Jaw was described for the first time in 2003 in a case series of 36 patients treated with zoledronic or pamidronic acid [1]. The authors described painful exposure of the maxilla and mandible that did not react to surgical nor pharmacological treatment [1]. Numerous case reports of this condition were published since and its nomenclature has been changing [2-4]. Due to the increasing number of described cases of antiresorptive drug-related osteonecrosis of the jaw bones, in 2014 the American Association of Oral and Maxillofacial Surgeons (AAOMS) suggested the term Medication Related Osteonecrosis of the Jaw (MRONJ) [4]. According to the current literature, osteonecrosis is a complication of treatment with bisphosphonates, denosumab and angiogenesis inhibitors [4-7].

Diagnostic criteria of MRONJ

The AAOMS position paper from 2014 indicate that MRONJ can be suspected if all of the following criteria are met:

• ongoing or past treatment with angiogenesis inhibitors or antiresorptive drugs,
• exposed facial/jaw bone or an extraoral fistula in the maxilla-facial area lasting > 8 weeks,
• no previous history of head and neck radiotherapy,
• lack of metastases to the jaw bones [4].

Clinically, a patient with MRONJ may present with exposed jaw bone with a focus of necrosis, pathological fracture of jaw bone, pain, inflammation, tooth movement, extraoral fistula, oral antral or oral nasal communication [4, 8-9] [see Figures 1-3].

Figure 1. Example of Medication-Related Osteonecrosis of the Jaw. A 75-year old male patient received 4 mg zolendronic acid iv every month between XI 2018 – X 2019 as a treatment for prostate cancer 

A. Multifocally exposed bone and purulence observed in the region of the left body of the mandible; the possible cause of MRONJ occurrence was unfitting partial denture in mandibula

B. Cone beam computed tomography showed excessive osteolysis in mandibular alveolar bone area

photo source: author's own materials

Figure 2. Example of Medication-Related Osteonecrosis of the Jaw. A 64-year old female patient received 4mg zolendronic acid iv every month between X 2017 – X 2019 as a treatment of breast cancer metastases

A. Exposed bone was observed in the region corresponding to tooth 14-15; the possible cause of MRONJ occurence was extraction of tooth 15 and following wear of unfitted partial denture.

B. Panoramic radiography disclosed alveolar bone loss in region corresponding to teeth 14-15. 

Figure 3. Example of Medication-Related Osteonecrosis of the Jaw. A male patient received 4mg zolendronic acid as a adjuvant treatment of multiple myeloma Exposed bone was observed in the right side of the mandibula; the possible cause of MRONJ occurence was extraction of teeth in above mentioned area.

photo source: author's own materials

Because MRONJ is a relatively new diagnosis, the literature about its treatment is scant and often limited to case reports. Several national and international dental and maxillo-facial surgery associations published MRONJ treatment guidelines [4-7]. However, these guidelines are often divergent due to a limited number of treated patients and different institutional experience [10]. The treatment strategy suggested by the AAOMS seems to be useful as it is based on the assessment of MRONJ severity which then guides the decision about appropriate treatment [4, 6] [see Table 1]. Infection control, analgesia and stopping the progression of osteonecrosis are key elements of MRONJ treatment [6].

Table 1. Treatment strategies according to the severity of MRONJ (modified from the 2014 AAOMS Guidelines)

Antiresorptive drugs

Bisphosphonates are group of drugs indicated for osteoporosis, osteopenia, Paget’s disease of the bone, osteogenesis imperfecta, prevention of hypercalcemia and metastasis to the bones [1, 3-4, 8, 11]. By binding to the bone matrix, bisphosphonates exert their antiresorptive activity at several stages, e.g. inhibition of osteoclast precursors’ maturation, inhibition of mature osteoclast recruitment, reduction of osteoclast activity by inducing their apoptosis [6, 8]. Thanks to their ability to bind with the bone matrix, the therapeutic effect of bisphosphonates may last up to 10 years after discontinuation of doses [4, 8]. Low-dose (oral) bisphosphonates such as alendronic acid, ibandronic acid and risedronic acid are used in majority of their indications described above [6]. However, ibandronic acid, pamidronic acid and zolendronic acid may also be administered intravenously (iv) once every 3 months and once a year, respectively, to treat the same illnesses. High doses of iv bisphosphonates, such as ibandronic acid, pamidronic acid and zoledronic acid are most commonly administered for prevention of metastasis to the bones in the course of multiple myeloma or cancer of the breast, lungs and prostate [4, 6, 8].

Denosumab is a human monoclonal IgG2 antibody which inhibits the activation of osteoclasts and their precursors by selectively binding the receptor activator of nuclear factor k-B ligand (RANKL) on their surfaces [12]. This results in inhibition of maturation, function and longevity of osteoclasts, thus reducing bone resorption [2, 6]. Unlike bisphosphonates, denosumab does not bind with the bone matrix, thus its effect is minimal 12-24 months after discontinuation [8]. Low doses of denosumab are indicated for osteoporosis and prevention of bone metastasis (subcutaneous every 6 months), whereas high doses are administered for the treatment of bone metastases (subcutaneous every 4 weeks) [6].

Angiogenesis inhibitors are indicated in cancer treatment where they limit tumor and metastasis growth [8, 13]. Of all the drugs in this group, anti-VEGF (vascular endothelial growth factor) and TKI (tyrosine kinase inhibitor) seem to correlate with higher risk of MRONJ [14-16]. Similarly to denosumab, angiogenesis inhibitors do not bind with bone matrix and are metabolized up to 20 days after discontinuation [6-7].

Discussion

Prevention of MRONJ should be based on qualification of patients to their appropriate MRONJ risk group, assessment of possible additional risk factors and formulating individual treatment recommendations [7]. Drug dose, duration of treatment and presence of additional MRONJ risk factors determine the patient’s risk of MRONJ [6] [Table 2].

Table 2. Risk group assessment

* MRONJ risk factor: antiresorptive drugs, corticosteroids, chemotherapy, poor oral hygiene, periodontal disease, poorly fitted dentures, cigarette smoking, comorbidities (cancer, hematologic disease, immune system diseases, diabetes, anemia)

Up to 90% of MRONJ cases occur in oncological patients treated with high-dose antiresorptive drugs [6]. Osteonecrosis is usually caused by a local oral infection or injury of mucosa or bone [6-7]. The most common risk factor related to the oral cavity is tooth extraction (45-61%), periodontal disease (10%) and poorly fitted dentures [3, 7, 17-18] [Table 3]. That is why cooperation between physicians and dentists is crucial in successful prevention of MRONJ [19-21]. Literature points out that MRONJ risk is lower among patients who were referred to a dentist and preventive procedures were performed [6, 22-23].

Table 3. MRONJ local risk factors (according to AAOMS 2014)

The specific preventive measures are dictated by assessing the patient’s risk of MRONJ and by the stage of treatment with antiresorptive drugs [6, 21, 23]. Regardless of their MRONJ risk, all patients should be examined by a dentist and instructed about oral cavity hygiene [5-6, 19, 24]. In addition, the dentist should perform oral cavity sanation, perform periodontal treatment and check if the patient’s dentures fit properly. The patient should be informed about the symptoms of MRONJ and the necessity of reporting them early [6].

After starting therapy with angiogenesis inhibitors or antiresorptive drugs, low-risk patients may undergo required and/or recommended dental treatment [5-7, 19, 24].

A different approach is required for patients with high risk of MRONJ. A dental consultation is recommended before any surgical, periodontal or dental implant procedure. Information from the physician supervising the antiresorptive drug therapy is also required [6, 21].

Literature suggests that lack of cooperation between physicians and dentists is correlated with a higher incidence of MRONJ [25]. Dentists may be the first doctors who diagnose signs of MRONJ, and patients with such diagnosis need to be referred to a maxillofacial surgery center for specialized treatment [23]. Regardless of their risk of MRONJ, patients treated with antiresorptive drugs need to complete dental hygiene training and have a follow-up visit every 4 months [7].

Conclusions

Increased incidence of MRONJ forces a multi-disciplinary cooperation between dentists and the physicians who are treating the underlying illness. The dentist may be the first doctor who diagnoses signs of MRONJ and initiates treatment, thus increasing the likelihood of good outcome. Currently there is no defined MRONJ treatment algorithm, so it is critical to implement preventive measures before starting antiresorptive drug treatment. Patients who are qualified for treatment with angiogenesis inhibitors or antiresorptive drugs should undergo dental examination and undergo full oral sanation in order to reduce the risk of complications

Acknowledgments: The authors thank dr Hanna Sobczak, Oral Surgeon, who kindly provided clinical advice and guidance.

Confllict of interests: None declared.